Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
By E. Van Cutsem, C. Köhne, I. Láng, G. Folprecht, M. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar and 5 more. Journal of Clinical Oncology, 2011
1,899 citations recorded by the source corpus.
PURPOSE The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken. PATIENTS AND METHODS Patients were randomly assigned to receive FOLFIRI with or without cetuximab. DNA was extracted from additional slide-mounted tumor samples previously used to assess epidermal growth factor receptor expression. Clinical outcome according to the tumor mutation status of KRAS and BRAF was assessed in the expanded patient series. RESULTS The ascertainment rate of patients analyzed for tumor KRAS status was increased from 45% to 89%, with mutations detected in 37% of tumors. The addition of cetuximab to FOLFIRI in patients with KRAS wild-type disease resulted in significant improvements in overall survival (median, 23.5 v 20.0 months; hazard ratio [HR], 0.796; P = .0093), progression-free survival (median, 9.9 v 8.4 months; HR, 0.696; P = .0012), and response (rate 57.3% v 39.7%; odds ratio, 2.069; P < .001) compared with FOLFIRI alone. Significant interactions between KRAS status and treatment effect were noted for all key efficacy end points. KRAS mutation status was confirmed as a powerful predictive biomarker for the efficacy of cetuximab plus FOLFIRI. BRAF tumor mutation was a strong indicator of poor prognosis. CONCLUSION The addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type mCRC. BRAF tumor mutation is an indicator of poor prognosis.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/86d6c0146a6e40a4d22a4a3dfeda066ba6d44f43
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, methodology): “Study Design and Patients The CRYSTAL and FIRE-3 study designs, treatment parameters, andeligibilitycriteriahavebeenpreviously reported.(1-4)”
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011, background): “S2, and Supplementary Table S2), again in agreement with clinical evidence (7-12).”
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib (2012, background): “Indeed, patients with metastatic colorectal cancer harboring BRAF V600 mutations exhibit an approximately 70% increase in mortality when compared with patients who have wild-type BRAF (4, 5).”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “A BRAF mutation is a strong negative prognostic biomarker: indeed, patients with a BRAF mutant mCRC have a very poor prognosis [39].”
- Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, methodology): “A previous retrospective subgroup analysis investigated the association of tumor KRAS exon 2 mutation status and treatment outcome.(2)”
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (2015, neutral): “The most common disease types were colorectal cancer (37 patients), non–small-cell lung cancer (20), Erdheim–Chester disease or Langerhans’-cell histiocytosis (18), primary brain tumors (13), cholangiocarcinoma (8), anaplastic thyroid cancer (7), and multiple myeloma (5).”
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, background): “Independent from tumour localization, RAS mutant tumour status is known to be a very strong negative predictor for EGFR antibody therapy whilst, RAS wt tumour status is a relatively strong predictive marker for the efficacy of EGFR antibody therapy [43, 45, 46, 58].”